APRE Aprea Therapeutics Inc

Price (delayed)

$4.20

Market cap

$88.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.55

Enterprise value

$11.63M

Sector: Healthcare
Industry: Biotechnology

Highlights

The debt has declined by 44% year-on-year and by 23% since the previous quarter
The quick ratio has contracted by 35% YoY but it has grown by 19% from the previous quarter
Aprea Therapeutics's net income has shrunk by 58% YoY
The equity has contracted by 39% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of APRE
Market
Shares outstanding
21.19M
Market cap
$88.98M
Enterprise value
$11.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.29
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$53.74M
EBITDA
-$53.51M
Free cash flow
-$45.8M
Per share
EPS
-$2.55
Free cash flow per share
-$2.16
Book value per share
$3.26
Revenue per share
$0
TBVPS
$3.79
Balance sheet
Total assets
$80.39M
Total liabilities
$11.25M
Debt
$259,300
Equity
$69.15M
Working capital
$68.87M
Liquidity
Debt to equity
0
Current ratio
7.14
Quick ratio
6.92
Net debt/EBITDA
1.45
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-55%
Return on equity
-64%
Return on invested capital
N/A
Return on capital employed
-77.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APRE stock price

How has the Aprea Therapeutics stock price performed over time
Intraday
1.94%
1 week
-0.94%
1 month
-9.68%
1 year
-88.36%
YTD
-14.63%
QTD
-17.65%

Financial performance

How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$51.13M
Net income
-$53.75M
Gross margin
N/A
Net margin
N/A
Aprea Therapeutics's net income has shrunk by 58% YoY
Aprea Therapeutics's operating income has decreased by 38% YoY but it has increased by 3.2% from the previous quarter

Growth

What is Aprea Therapeutics's growth rate over time

Valuation

What is Aprea Therapeutics stock price valuation
P/E
N/A
P/B
1.29
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
APRE's EPS is down by 19% year-on-year
APRE's P/B is 69% below its last 4 quarters average of 4.2
The equity has contracted by 39% YoY and by 11% from the previous quarter

Efficiency

How efficient is Aprea Therapeutics business performance
The company's return on equity has shrunk by 113% YoY and by 14% QoQ
Aprea Therapeutics's ROA has plunged by 102% YoY and by 12% from the previous quarter

Dividends

What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APRE.

Financial health

How did Aprea Therapeutics financials performed over time
The company's total assets fell by 36% YoY and by 13% QoQ
The quick ratio has contracted by 35% YoY but it has grown by 19% from the previous quarter
The debt is 100% smaller than the equity
The debt has declined by 44% year-on-year and by 23% since the previous quarter
The equity has contracted by 39% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.